BUHLMANN News - Buhlmann Diagnostics Corp - Newsletter - Tradeshow

BUHLMANN News

Buhlmann – Next Generation Food Allergy Drug Development Summit

Next Generation Food Allergy Drug Development Summit, July 20-22, 2021: BUHLMANN is proud to partner with this event, specifically focused ...
Read More

Digestive Disease Week 2021

Assays Offerings We offer the broadest fecal calprotectin (fCAL) product range in the industry, available in the United States, including ...
Read More

Visit BUHLMANN at AACC 2021 (LIVE)

Assays Offerings We offer the broadest fecal calprotectin (fCAL) product range in the industry, available in the United States, including ...
Read More

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics

Announcement BUHLMANN Diagnostic Corp is pleased to announce a new partner channel agreement with Roche Diagnostics for the launch and ...
Read More

Educational Webinar recording from AMLI presentation by Dr Arne Roseth

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a ...
Read More

Use of basophil activation in oral immunotherapy

New JACI paper from Patil et al: Food allergy is a growing public health burden in children and adults all ...
Read More

CALEX Cap Promotion

BÜHLMANN fCAL® turbo + CALEX® Cap (K191718): FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 98839 CALEX® Cap CALEX® Cap is an ...
Read More

LabSense News Q1 2020 Edition

In this "Q1 2020 Edition"of BUHLMANN's LabSense News, we are proud to introduce Quantum Blue® Anti-Infliximab (RUO) and Anti-Adalimumab (RUO) to the TDM rapid ...
Read More